Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Open Ophthalmology"
DOI: 10.1136/bmjophth-2017-000102
Abstract: Purpose Antivascular endothelial growth factor (anti-VEGFs)—bevacizumab is routinely utilised for the treatment of diabetic macular oedema (DME). We plan to evaluate the impact of bevacizumab on the central subfield macular thickness (CSMT) of the treated… read more here.
Keywords: untreated eye; patients bilateral; macular oedema; diabetic macular ... See more keywords